CL2019000185A1 - Aumento de la fertilidad en especies bovinas. - Google Patents

Aumento de la fertilidad en especies bovinas.

Info

Publication number
CL2019000185A1
CL2019000185A1 CL2019000185A CL2019000185A CL2019000185A1 CL 2019000185 A1 CL2019000185 A1 CL 2019000185A1 CL 2019000185 A CL2019000185 A CL 2019000185A CL 2019000185 A CL2019000185 A CL 2019000185A CL 2019000185 A1 CL2019000185 A1 CL 2019000185A1
Authority
CL
Chile
Prior art keywords
increase
fertility
bovine species
bovine
species
Prior art date
Application number
CL2019000185A
Other languages
English (en)
Inventor
Albert Abraham
Jason Nickell
Daniel Keil
Warren Tully
Riekerink Richard Gerhardus Martinu Olde
Leland Vickers
Stuart Nibbelink
Terry Settje
Original Assignee
Bayer Animal Health Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Animal Health Gmbh filed Critical Bayer Animal Health Gmbh
Publication of CL2019000185A1 publication Critical patent/CL2019000185A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dispersion Chemistry (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A COMPOSICIONES Y MÉTODOS DE INMUNOMODULACIÓN QUE SON EFICACES PARA AUMENTAR EL PORCENTAJE DE CONCEPCIÓN EN VACAS.
CL2019000185A 2016-07-26 2019-01-24 Aumento de la fertilidad en especies bovinas. CL2019000185A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662366772P 2016-07-26 2016-07-26

Publications (1)

Publication Number Publication Date
CL2019000185A1 true CL2019000185A1 (es) 2019-06-28

Family

ID=59700165

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019000185A CL2019000185A1 (es) 2016-07-26 2019-01-24 Aumento de la fertilidad en especies bovinas.

Country Status (21)

Country Link
US (1) US10933131B2 (es)
EP (1) EP3490598A1 (es)
JP (1) JP2019525935A (es)
KR (1) KR102473370B1 (es)
CN (1) CN109689095B (es)
AR (1) AR109167A1 (es)
AU (1) AU2017301528A1 (es)
BR (1) BR112019001599A2 (es)
CA (1) CA3031778A1 (es)
CL (1) CL2019000185A1 (es)
CO (1) CO2019000724A2 (es)
CR (1) CR20190037A (es)
DO (1) DOP2019000018A (es)
IL (1) IL264380A (es)
MX (1) MX2019001126A (es)
NZ (1) NZ750181A (es)
PE (1) PE20190566A1 (es)
SG (1) SG11201900710YA (es)
TW (1) TWI759317B (es)
UY (1) UY37346A (es)
WO (1) WO2018022583A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102514899B1 (ko) * 2022-03-04 2023-03-29 경북대학교 산학협력단 암소 번식 능력 개선용 조성물

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US4812314A (en) * 1986-02-24 1989-03-14 Yissum Research & Dev. Co. Of The Hebrew Univ. Of Jerusalem And Hadassah Medical Organization Lipid replacement therapy
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US6693086B1 (en) 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
DK1221955T3 (da) * 1999-09-25 2006-01-30 Univ Iowa Res Found Immunstimulerende nukleinsyre
JP2005532067A (ja) * 2002-07-03 2005-10-27 コーリー ファーマシューティカル グループ，インコーポレイテッド 刺激性免疫応答用の核酸組成物
AU2002953015A0 (en) 2002-12-02 2002-12-12 Women's And Children's Hospital Modified lacz gene
CA2577270A1 (en) 2004-08-13 2006-02-16 The Trustees Of The University Of Pennsylvania Antibiotic resistance free dna vaccines
WO2010130374A1 (en) 2009-05-14 2010-11-18 Bayer Animal Health Gmbh Enhanced immune response in avian species
EP2654785B1 (en) * 2010-12-22 2019-03-20 Bayer Intellectual Property GmbH Enhanced immune response in bovine species
CA2820499A1 (en) * 2013-06-18 2014-12-18 Bayer Intellectual Property Gmbh Enhanced immune response in bovine species
RU2530520C1 (ru) * 2013-08-02 2014-10-10 Государственное научное учреждение Научно-исследовательский ветеринарный институт Нечернозёмной зоны Российской Федерации Российской академии сельскохозяйственных наук Средство для оптимизации воспроизводительной функции коров
MX2016010993A (es) 2014-02-28 2017-05-01 Bayer Animal Health Gmbh Plasmidos inmunoestimuladores.
US20190233825A1 (en) 2015-06-26 2019-08-01 Bayer Animal Health Gmbh Methods of modulating cytosolic dna surveillance molecules
JP2018521108A (ja) 2015-07-31 2018-08-02 バイエル・アニマル・ヘルス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ａｎｉｍａｌ Ｈｅａｌｔｈ Ｇｍｂｈ 水生種における免疫応答の増強
CA2993883A1 (en) 2015-07-31 2017-02-09 Bayer Animal Health Gmbh Enhanced immune response in porcine species

Also Published As

Publication number Publication date
AU2017301528A1 (en) 2019-02-14
CR20190037A (es) 2019-05-16
SG11201900710YA (en) 2019-02-27
KR102473370B1 (ko) 2022-12-05
IL264380A (en) 2019-02-28
BR112019001599A2 (pt) 2019-10-01
UY37346A (es) 2018-02-28
KR20190032434A (ko) 2019-03-27
JP2019525935A (ja) 2019-09-12
MX2019001126A (es) 2019-08-14
CN109689095A (zh) 2019-04-26
EP3490598A1 (en) 2019-06-05
AR109167A1 (es) 2018-11-07
DOP2019000018A (es) 2019-07-31
CA3031778A1 (en) 2018-02-01
US20190388538A1 (en) 2019-12-26
NZ750181A (en) 2023-02-24
TWI759317B (zh) 2022-04-01
US10933131B2 (en) 2021-03-02
CO2019000724A2 (es) 2019-02-08
CN109689095B (zh) 2023-10-03
WO2018022583A1 (en) 2018-02-01
TW201817427A (zh) 2018-05-16
PE20190566A1 (es) 2019-04-22

Similar Documents

Publication Publication Date Title
CL2018001368A1 (es) Composiciones que comprenden cepas bacterianas
CL2019000061A1 (es) Anticuerpo para anti-claudin 18a2 y su utilización.
CO2017013443A2 (es) Composiciones que comprenden cepas bacterianas del género blautia
BR112017025004A2 (pt) composições compreendendo cepas bacterianas
PE20180266A1 (es) Composiciones que comprenden cepas bacterianas
CL2018001349A1 (es) Composiciones que comprenden cepas bacterianas
CL2017003389A1 (es) Composiciones de pienso para animales y usos de las mismas.
CO2017007671A2 (es) Composiciones para modular la expresión de c9orf72
CL2019000230A1 (es) Composiciones y métodos de inhibición del masp-3 para el tratamiento de diversas enfermedades y trastornos.
BR112018010089A2 (pt) composições compreendendo cepas bacterianas
BR112018009213A2 (pt) composições compreendendo cepas bacterianas
BR112019006160A2 (pt) composições e métodos para o tratamento das condições oftálmicas
UY37134A (es) Compuestos heteroarilos y composiciones que los contienen útiles como inhibidores de pad4
BR112017003414A2 (pt) composições compreendendo caseína e métodos para produzir as mesmas
MX2022007816A (es) Compuestos eficaces en el tratamiento de la hepatotoxicidad y enfermedades de higado graso, y uso de los mismos.
CL2016000326A1 (es) Composiciones y método para tratar condiciones asociadas con el complemento
CL2018000451A1 (es) Composiciones de micropartículas que comprenden saflufenacil
MX2017003944A (es) Combinacion de un acido graso omega-3 y un inhibidor de sglt-2 para tratar enfermedades hepaticas.
BR112018012313A2 (pt) composições que compreendem 15-hepe e métodos para uso das mesmas
BR112018012304A2 (pt) composições e métodos para diminuir expressão de tau
ECSP19090645A (es) Composición que comprende manosa oligosacárido y proceso para realizarla y uso de esta
CL2018001788A1 (es) Composiciones y métodos para evaluar el riesgo de ocurrencia de cáncer.
SV2018005613A (es) Agentes, usos y metodos para el tratamiento
CL2018003377A1 (es) Compuestos novedosos para tratar enfermedades parasitarias. (divisional solicitud 201803187)
CL2023000892A1 (es) Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b (divisional).